Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis

NCT01191255 is registered in ClinicalTrials.gov with Keryx Biopharmaceuticals as lead sponsor.

NCT NCT01191255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01191255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Lead sponsor
Keryx Biopharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2010
Completion date
February 28, 2013
Enrollment
441 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

hyperphosphatemia, kidney failure